RIGL PE Ratio & Valuation, Is RIGL Overvalued

Historical Valuation

Rigel Pharmaceuticals Inc (RIGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.88 is considered Undervalued compared with the five-year average of -3.88. The fair price of Rigel Pharmaceuticals Inc (RIGL) is between 82.36 to 110.14 according to relative valuation method. Compared to the current price of 28.44 USD , Rigel Pharmaceuticals Inc By Undervalued By 65.47%.

Relative Value

Fair Zone

82.36-110.14

Current Price：28.44

65.47%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Rigel Pharmaceuticals Inc (RIGL) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Rigel Pharmaceuticals Inc (RIGL) has a current Price-to-Book (P/B) ratio of 6.45. Compared to its 3-year average P/B ratio of 0.99, the current P/B ratio is approximately 549.34% higher. Relative to its 5-year average P/B ratio of 1.13, the current P/B ratio is about 469.13% higher. Rigel Pharmaceuticals Inc (RIGL) has a Forward Free Cash Flow (FCF) yield of approximately 8.97%. Compared to its 3-year average FCF yield of -2.91%, the current FCF yield is approximately -408.27% lower. Relative to its 5-year average FCF yield of -7.38%, the current FCF yield is about -221.56% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RIGL competitors is 32.93, providing a benchmark for relative valuation. Rigel Pharmaceuticals Inc Corp (RIGL.O) exhibits a P/S ratio of 2.88, which is -91.25% above the industry average. Given its robust revenue growth of 21.19%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RIGL increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RIGL in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RIGL currently overvalued or undervalued?

Rigel Pharmaceuticals Inc (RIGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.88 is considered Undervalued compared with the five-year average of -3.88. The fair price of Rigel Pharmaceuticals Inc (RIGL) is between 82.36 to 110.14 according to relative valuation method. Compared to the current price of 28.44 USD, Rigel Pharmaceuticals Inc is Undervalued By 65.47%.

What is Rigel Pharmaceuticals Inc (RIGL) fair value?

RIGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Rigel Pharmaceuticals Inc (RIGL) is between 82.36 to 110.14 according to relative valuation method.

How does RIGL's valuation metrics compare to the industry average?

The average P/S ratio for RIGL's competitors is 32.93, providing a benchmark for relative valuation. Rigel Pharmaceuticals Inc Corp (RIGL) exhibits a P/S ratio of 2.88, which is -91.25% above the industry average. Given its robust revenue growth of 21.19%, this premium appears sustainable.

What is the current P/B ratio for Rigel Pharmaceuticals Inc (RIGL) as of Mar 12 2026?

As of Mar 12 2026, Rigel Pharmaceuticals Inc (RIGL) has a P/B ratio of 6.45. This indicates that the market values RIGL at 6.45 times its book value.

What is the current FCF Yield for Rigel Pharmaceuticals Inc (RIGL) as of Mar 12 2026?

As of Mar 12 2026, Rigel Pharmaceuticals Inc (RIGL) has a FCF Yield of 8.97%. This means that for every dollar of Rigel Pharmaceuticals Inc's market capitalization, the company generates 8.97 cents in free cash flow.

What is the current Forward P/E ratio for Rigel Pharmaceuticals Inc (RIGL) as of Mar 12 2026?

As of Mar 12 2026, Rigel Pharmaceuticals Inc (RIGL) has a Forward P/E ratio of 10.25. This means the market is willing to pay $10.25 for every dollar of Rigel Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Rigel Pharmaceuticals Inc (RIGL) as of Mar 12 2026?

As of Mar 12 2026, Rigel Pharmaceuticals Inc (RIGL) has a Forward P/S ratio of 2.88. This means the market is valuing RIGL at $2.88 for every dollar of expected revenue over the next 12 months.

RIGL Valuation